Towa Pharmaceutical バランスシートの健全性

財務の健全性基準チェック /36

Towa Pharmaceuticalの総株主資本は¥159.1B 、総負債は¥213.4Bで、負債比率は134.1%となります。総資産と総負債はそれぞれ¥442.8Bと¥283.7Bです。 Towa Pharmaceuticalの EBIT は¥21.2Bで、利息カバレッジ比率19.1です。現金および短期投資は¥41.3Bです。

主要情報

134.1%

負債資本比率

JP¥213.40b

負債

インタレスト・カバレッジ・レシオ	19.1x
現金	JP¥41.27b
エクイティ	JP¥159.11b
負債合計	JP¥283.73b
総資産	JP¥442.84b

財務の健全性に関する最新情報

Is Towa Pharmaceutical (TSE:4553) A Risky Investment?

Nov 13

Recent updates

Fewer Investors Than Expected Jumping On Towa Pharmaceutical Co., Ltd. (TSE:4553)

Aug 03

Towa Pharmaceutical's (TSE:4553) Earnings Are Weaker Than They Seem

Jul 03

財務状況分析

短期負債: 4553の短期資産 ( ¥227.2B ) が短期負債 ( ¥74.7B ) を超えています。

長期負債: 4553の短期資産 ( ¥227.2B ) が長期負債 ( ¥209.0B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 4553の純負債対資本比率 ( 108.2% ) は高いと見なされます。

負債の削減: 4553の負債対資本比率は、過去 5 年間で64%から134.1%に増加しました。

債務返済能力: 4553の負債は営業キャッシュフローによって十分にカバーされていません ( 10% )。

インタレストカバレッジ: 4553の負債に対する利息支払いは EBIT ( 19.1 x coverage) によって十分にカバーされています。

Towa Pharmaceutical バランスシートの健全性

財務の健全性 基準チェック /36

主要情報

財務の健全性に関する最新情報

Is Towa Pharmaceutical (TSE:4553) A Risky Investment?

Recent updates

Consensus EPS estimates increase by 25%

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Towa Pharmaceutical (TSE:4553) A Risky Investment?

Upcoming dividend of JP¥30.00 per share

Towa Pharmaceutical (TSE:4553) Will Pay A Dividend Of ¥30.00

Towa Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 12, 2024

Consensus EPS estimates increase by 11%

Towa Pharmaceutical (TSE:4553) Is Due To Pay A Dividend Of ¥30.00

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

Fewer Investors Than Expected Jumping On Towa Pharmaceutical Co., Ltd. (TSE:4553)

Final dividend of JP¥30.00 announced

Towa Pharmaceutical's (TSE:4553) Earnings Are Weaker Than They Seem

New minor risk - Earnings quality

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 08, 2024

Towa Pharmaceutical Co., Ltd. Files New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the Rivastigmine Twice Weekly Transdermal Patch for Treating Mild to Moderate Dementia Associated with Alzheimer's Disease

Towa Pharmaceutical Co., Ltd. Announces Board and Committee Resignations

Price target decreased by 8.1% to JP¥3,393

Full year 2024 earnings: EPS exceeds analyst expectations

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Upcoming dividend of JP¥30.00 per share

Price target increased by 7.6% to JP¥3,690

Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Consensus EPS estimates increase by 38%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 20%

Towa Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 13, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to JP¥3,150

Towa Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 13, 2023

Upcoming dividend of JP¥30.00 per share at 2.1% yield

Price target increased by 18% to JP¥2,228

Consensus EPS estimates increase by 14%

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Dividend sustainability

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥30.00 per share at 3.2% yield

Price target decreased by 11% to JP¥2,120

Price target decreased by 13% to JP¥2,370

Third quarter 2023 earnings released: JP¥14.38 loss per share (vs JP¥117 profit in 3Q 2022)

Towa Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 19%

Less than half of directors are independent

Upcoming dividend of JP¥30.00 per share

Towa Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to JP¥2,800

Towa Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 10, 2022

Price target decreased to JP¥3,167

Full year 2022 earnings: EPS and revenues miss analyst expectations

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Upcoming dividend of JP¥33.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings released: EPS JP¥79.88 (vs JP¥59.25 in 2Q 2021)

Investor sentiment deteriorated over the past week

Price target increased to JP¥3,364

Upcoming dividend of JP¥27.00 per share

Price target increased to JP¥3,084

First quarter 2022 earnings released: EPS JP¥108 (vs JP¥67.77 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥284 (vs JP¥295 in FY 2020)

Upcoming dividend of JP¥22.00 per share

Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021

Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan

New 90-day high: JP¥2,237

Third quarter 2021 earnings released: EPS JP¥64.94 (vs JP¥79.32 in 3Q 2020)

財務の健全性基準チェック /36